Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) EBITDA Margin: 2021-2025

Historic EBITDA Margin for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to -102.64%.

  • Rhythm Pharmaceuticals' EBITDA Margin rose 2934.00% to -102.64% in Q3 2025 from the same period last year, while for Sep 2025 it was -106.81%, marking a year-over-year increase of 12914.00%. This contributed to the annual value of -204.04% for FY2024, which is 3407.00% up from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported EBITDA Margin of -102.64% as of Q3 2025, which was down 9.91% from -93.39% recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year EBITDA Margin high stood at -93.39% for Q2 2025, and its period low was -98,280.00% during Q1 2021.
  • Its 3-year average for EBITDA Margin is -210.40%, with a median of -143.73% in 2025.
  • In the last 5 years, Rhythm Pharmaceuticals' EBITDA Margin spiked by 9,476,258bps in 2022 and then crashed by 8,068bps in 2024.
  • Rhythm Pharmaceuticals' EBITDA Margin (Quarterly) stood at -2,806.22% in 2021, then skyrocketed by 232,723bps to -478.99% in 2022, then surged by 30,871bps to -170.28% in 2023, then skyrocketed by 7,165bps to -98.63% in 2024, then surged by 2,934bps to -102.64% in 2025.
  • Its EBITDA Margin stands at -102.64% for Q3 2025, versus -93.39% for Q2 2025 and -143.73% for Q1 2025.